Multi-omics Mendelian Randomization Reveals Immunometabolic Signatures of the Gut Microbiota in Optic Neuritis and the Potential Therapeutic Role of Vitamin B6
- PMID: 40214955
- PMCID: PMC12289774
- DOI: 10.1007/s12035-025-04923-4
Multi-omics Mendelian Randomization Reveals Immunometabolic Signatures of the Gut Microbiota in Optic Neuritis and the Potential Therapeutic Role of Vitamin B6
Abstract
Optic neuritis (ON) is an inflammatory condition often linked to autoimmune disorders like multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Despite its low incidence, ON can lead to severe, irreversible visual impairment. Emerging evidence suggests the gut microbiota (GM) may influence ON through complex immune and metabolic pathways, yet the mechanisms remain underexplored. This study employed a multi-omics Mendelian randomization (MR) approach to assess the causal relationships between GM taxa and ON. We analyzed data from extensive genetic and metabolic profiling, examining the causal effect between 473 GM taxa, 731 immune cells/traits, 1400 metabolites, vitamin B6, and ON. Our methodology involved two-sample MR analysis to establish causality and mediation analysis to explore the mechanisms between GM and ON and potential therapeutic strategies. We identified 27 GM taxa with a direct causal relationship to ON risk. Further analysis highlighted three GM taxa with particularly strong associations. Mediation analysis revealed specific metabolic and immune pathways through which these taxa exert their effects, including notable interactions with vitamin B6 metabolism, which appeared to mediate some of these relationships. We found that vitamin B6 could be a potential therapeutic method by acting on GM in ON. This study advances our understanding of the complex etiology of ON and highlights the potential of GM as a target for therapeutic strategies. The significant role of vitamin B6 suggests new avenues for prevention and treatment, emphasizing the need for further research into diet-based interventions.
Keywords: Gut microbiota; Immune cells; Mendelian randomization; Optic neuritis; Vitamin B6.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics Approval and Consent to Participate: Since the data adopted in this study were all publicly available data from the FinnGen database, UK Biobank, all data-related studies were approved by their respective ethical review committees and received written informed consent from patients. Therefore, this study does not need additional ethics approval. Consent for Publication: Not applicable as this manuscript does not contain any individual person’s data in any form that requires consent for publication. Competing interests: The authors declare no competing interests.
Figures





Similar articles
-
Gut microbiota causally affects ulcerative colitis by potential mediation of plasma metabolites: A Mendelian randomization study.Medicine (Baltimore). 2025 Jun 27;104(26):e42791. doi: 10.1097/MD.0000000000042791. Medicine (Baltimore). 2025. PMID: 40587710 Free PMC article.
-
Inflammatory cytokines mediate the gut microbiota-EGPA subtype link: a Mendelian randomization study.Clin Rheumatol. 2025 Jul;44(7):3061-3071. doi: 10.1007/s10067-025-07526-5. Epub 2025 Jun 12. Clin Rheumatol. 2025. PMID: 40500572
-
Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.Curr Neurol Neurosci Rep. 2025 Jul 1;25(1):45. doi: 10.1007/s11910-025-01432-8. Curr Neurol Neurosci Rep. 2025. PMID: 40591029 Review.
-
Gut microbiota constituents may affect hypertrophic scarring risk through interaction with specific immune cells in a two-step, two-sample Mendelian randomization study.Sci Rep. 2025 Jul 1;15(1):20656. doi: 10.1038/s41598-025-07455-y. Sci Rep. 2025. PMID: 40596527 Free PMC article.
-
The effect of vitamin B6 on cognition.Cochrane Database Syst Rev. 2003;(4):CD004393. doi: 10.1002/14651858.CD004393. Cochrane Database Syst Rev. 2003. PMID: 14584010
References
-
- Bennett JL, Costello F, Chen JJ et al (2023) Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol 22(1):89–100 - PubMed
-
- Toosy AT, Mason DF, Miller DH (2014) Optic neuritis. Lancet Neurol 13(1):83–99 - PubMed
-
- Levy M, Fujihara K, Palace J (2021) New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 20(1):60–67 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous